Abstract: A device and method for controlling a power converter. The device includes an activation terminal configured to obtain a first voltage based on the input voltage; a controlling terminal configured to obtain a second voltage based on the output voltage; and a digital controller configured to obtain a driving power based on the first voltage and/or the second voltage; the digital controller is configured to obtain the driving power at least based on the first voltage when the power converter is stopped. Therefore, a sufficient driving power can be provided for the digital controller even when the power converter is stopped.

Abstract: A device and method for controlling a power converter. The device includes an activation terminal configured to obtain a first voltage based on the input voltage; a controlling terminal configured to obtain a second voltage based on the output voltage; and a digital controller configured to obtain a driving power based on the first voltage and/or the second voltage; the digital controller is configured to obtain the driving power at least based on the first voltage when the power converter is stopped. Therefore, a sufficient driving power can be provided for the digital controller even when the power converter is stopped.

Abstract: An alkali metal hydrogensulfite or sulfite is effective for controlling a local injury such as inflammation and vein injury occurring on the injection of an antitumor benzodiazepine compound of the formula ##STR1## wherein R.sub.1 denotes hydrogen atom, or acyl, carbamyl, or alkoxycarbonyl group; R.sub.2 denotes hydrogen atom or acyl group; and R.sub.3 denotes sulfinic acid rest, SO.sub.2 X, or sulfonic acid rest, SO.sub.3 X, X meaning hydrogen, alkali metal or alkaline earth metal. An aqueous solution containing the both can be administered by injection.

Abstract: A dry .gamma.-globulin preparation capable of intravenous injection which is obtainable by polyethylene glycol fractionation of plasma is improved in its water-solubility and stability against increase of anticomplement activity and decrease of antibody titer by purifying the .gamma.-globulin fraction with respect to protein to render the residual polyethylene glycol substantially not detectable in its 5% W/V solution, adding 0.2 to 2 parts by weight of glucose based on 1 part of .gamma.-globulin, and lyophilizing its solution.

Abstract: A reagent for determination of human blood coagulation factor XIII for reversed passive hemagglutination reaction which comprises sensitized erythrocytes prepared by sensitizing animal erythrocytes with specific anti-human factor XIII antibody, and a kit using the reagent are disclosed.

Abstract: Benzodiazepine derivative represented by the following general formula or pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 is --COR.sup.4 (R.sup.4 is a carboxylic acid residue) or an alkyl or aralkyl group (these groups have a substituent selected from a carboxyl group, an amino group and a cyano group), R.sup.2 is a lower alkyl group and R.sup.3 is a hydrogen atom or a lower alkyl group.The above compound is low in toxicity and has an antitumor activity.

Abstract: A lyophylized cold insoluble globulin preparation can be prepared in stable condition and in short time by lyophylizing an aqueous solution of a cold insoluble globulin in the presence of albumin and a neutral amino acid, a monosaccharide, a disaccharide or a sugar alcohol. The preparation dissolves in water without occurrence of turbidity and is usable for injection.

Abstract: A process for producing a hepatitis B infection preventing vaccine containing hepatitis B surface antigen as a main component thereof which comprises removing human plasma components possibly causing adverse effects and components capable of causing hepatitis B infection by incorporating steps of fractionation using ammonium sulfate, adsorption on a colloidal silicate and fractionation using polyethylene glycol into the purification stage after heat treatment and further carrying out a treatment for infectivity inactivation without causing any antigenicity impairment.

Abstract: Physiologically active substances such as antibiotics can preferentially be carried to a morbid part, for example, injured tissue and neoplastic cell proliferation site by administering its complex with fibronectin to repair the morbid part. The complex is prepared by the reaction between the physiologically active substance and the fibronectin with or without intervention of a protein cross-linking agent.

Abstract: Interferon can be recovered simply by contacting an aqueous solution containing interferon which is induced and produced from cells of human origin capable of producing interferon, with a siliceous substance to adsorb interferon on it and eluting the adsorbed interferon with an aqueous solution containing a nonionic surfactant, preferably further containing an acriflavine such as acrinol.

Abstract: Human urine-origin colony-stimulating factor and kallikrein are separated in pure form, respectively, from an aqueous solution thereof, such as a urinary protein-concentrated solution by subjecting the solution added with a stabilizer such as octyl-phenoxypolyethoxyethanaol or polyethylene glycol both having a molecular weight of 1,000-10,000, to high-performance gel filtration effective in molecular exclusive limit of 10.sup.5 -5.times.10.sup.5 as determined with globular protein.

Abstract: Complexes of albumin combined with organic dibasic acid half esters, such as those of succinic acid and phthalic acid, of 7-hydroxycholesterol are soluble in water and have excellent immunosuppressive and anti-inflammatory action.

Abstract: Cold insoluble globulin which may have hepatitis virus activity can be virus-inactivated with keeping at a minimum the damage of the cold insoluble globulin by heating its aqueous solution at 50.degree. to 80.degree. C. for 5 to 20 hours in the presence of 10% (W/V) or more of at least one principal stabilizer of neutral amino acids, monosaccharides, disaccharides, and sugar alcohols with or without 10% (W/V) or more of at least one auxiliary stabilizer of salts of hydrocarbon carboxylic acids or hydroxyhydrocarbon carboxylic acids both having 3 to 10 carbon atoms.

Abstract: A process for preparing immunoglobulin suitable for intravenous injection, comprising treating with an acid a plasma or fraction I+II+III, fraction II+III, fraction II, or fraction III (hereinafter these are sometimes referred collectively to as starting material) obtained from plasma by Cohn's cold alcohol fractionation method, and subjecting to fractionation using an alkylene oxide polymer or copolymer having a molecular weight of 2,000 to 20,000.

Abstract: A method for stabilizing plasminogen which comprises adding a physiologically acceptable inorganic salt to a plaminogen-containing aqueous solution to give a final concentration of the salt of 0.002 to 0.4 M.

Abstract: A process for recovering interferon which comprises contacting a solution containing an interferon produced by the induced cells of human origin with a water-insolubilized sulfated polysaccharide to allow the interferon to be adsorbed on the water-insolubilized sulfated polysaccharide and then selectively eluting the interferon with an aqueous solution of an inorganic salt.

Abstract: An antithrombin preparation, secure and stable for a long period of time, can be obtained by freeze-drying an aqueous solution containing antithrombin-III as main component in the presence of an effective quantity of at least one member selected from the group consisting of proteins, sugars, amino acids, inorganic salts and salts of organic acids as stabilizer.

Abstract: Novel isoquinoline derivatives of the general formula ##STR1## wherein R represents a lower alkyl group, a lower cycloalkyl group, or a group of the formula ##STR2##in which R.sup.2 represents a hydrogen atom, a halogen atom, a methyl group, a trifluoromethyl group, a methoxy group, a methylamino group or a dimethylami no group;R.sup.1 represents a hydrogen atom or a lower alkyl group; andY represents a carboxyl group, a cyano group, a carbamoyl group, a lower alkoxycarbonyl group or a lower alkylaminocarbonyl group;or a salt thereof; a process for the production thereof.The above compound is useful as an anti-inflammatory and analgesic agent.

Abstract: A method of treating hypoproteinemia is disclosed in which an enteric film coated IgA-rich gamma globulin is administered orally to a person suffering therefrom until total serum content and plasma content are restored. The film coating is soluble in neutral or alkaline media by insoluble in acid media.

Abstract: A process for heat treatment to inactive hepatitis virus in human blood coagulation factor XIII compositions, which is characterized in that the heat treatment at 50.degree. to 80.degree. C. of an aqueous solution containing the human blood coagulation factor XIII is carried out for 3 to 15 hours in the presence of 10% (W/V) or more of at least one principal stabilizer selected from the group consisting of neutral amino acids, monosaccharides and sugar alcohols and 10% (W/V) or more of at least one auxiliary stabilizer selected from the group consisting of salts of organic carboxylic acids having 3 to 10 carbon atoms.